B38-CAP

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameB38-CAP
Drug Alias NameRecombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)
ClassificationBiologics > Protein drugs > EnzymeNatural product/Extract > Microbial extract
Mechanisms of ActionAngiotensin-converting enzyme 2 inhibitors
TargetsAngiotensin-converting enzyme 2
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAkita University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKafrelsheikh University
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A